JP2010241830A5 - - Google Patents

Download PDF

Info

Publication number
JP2010241830A5
JP2010241830A5 JP2010162177A JP2010162177A JP2010241830A5 JP 2010241830 A5 JP2010241830 A5 JP 2010241830A5 JP 2010162177 A JP2010162177 A JP 2010162177A JP 2010162177 A JP2010162177 A JP 2010162177A JP 2010241830 A5 JP2010241830 A5 JP 2010241830A5
Authority
JP
Japan
Prior art keywords
amino
methyl
ethyl
dimethylamino
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010162177A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010241830A (ja
Filing date
Publication date
Priority claimed from GB0319227A external-priority patent/GB0319227D0/en
Priority claimed from GB0322370A external-priority patent/GB0322370D0/en
Application filed filed Critical
Publication of JP2010241830A publication Critical patent/JP2010241830A/ja
Publication of JP2010241830A5 publication Critical patent/JP2010241830A5/ja
Pending legal-status Critical Current

Links

JP2010162177A 2003-08-15 2010-07-16 新生物疾患、炎症および免疫障害の処置に有用な２，４−ピリミジンジアミン Pending JP2010241830A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0319227A GB0319227D0 (en) 2003-08-15 2003-08-15 Organic compounds
GB0322370A GB0322370D0 (en) 2003-09-24 2003-09-24 Organic compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006522998A Division JP4607879B2 (ja) 2003-08-15 2004-08-13 新生物疾患、炎症および免疫障害の処置に有用な２，４−ピリミジンジアミン

Publications (2)

Publication Number Publication Date
JP2010241830A JP2010241830A (ja) 2010-10-28
JP2010241830A5 true JP2010241830A5 (cg-RX-API-DMAC10.html) 2011-08-11

Family

ID=34196260

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006522998A Expired - Lifetime JP4607879B2 (ja) 2003-08-15 2004-08-13 新生物疾患、炎症および免疫障害の処置に有用な２，４−ピリミジンジアミン
JP2010162177A Pending JP2010241830A (ja) 2003-08-15 2010-07-16 新生物疾患、炎症および免疫障害の処置に有用な２，４−ピリミジンジアミン

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006522998A Expired - Lifetime JP4607879B2 (ja) 2003-08-15 2004-08-13 新生物疾患、炎症および免疫障害の処置に有用な２，４−ピリミジンジアミン

Country Status (31)

Country Link
US (2) US7893074B2 (cg-RX-API-DMAC10.html)
EP (2) EP2287156B1 (cg-RX-API-DMAC10.html)
JP (2) JP4607879B2 (cg-RX-API-DMAC10.html)
KR (1) KR100904570B1 (cg-RX-API-DMAC10.html)
AR (1) AR045458A1 (cg-RX-API-DMAC10.html)
AT (1) ATE542801T1 (cg-RX-API-DMAC10.html)
AU (2) AU2004264382A1 (cg-RX-API-DMAC10.html)
BR (2) BRPI0413616B8 (cg-RX-API-DMAC10.html)
CA (1) CA2533320A1 (cg-RX-API-DMAC10.html)
CO (1) CO5680434A2 (cg-RX-API-DMAC10.html)
CY (2) CY1112571T1 (cg-RX-API-DMAC10.html)
DK (2) DK1660458T3 (cg-RX-API-DMAC10.html)
EC (1) ECSP066371A (cg-RX-API-DMAC10.html)
ES (2) ES2424881T3 (cg-RX-API-DMAC10.html)
HR (2) HRP20120335T1 (cg-RX-API-DMAC10.html)
IL (1) IL173129A0 (cg-RX-API-DMAC10.html)
IS (1) IS2873B (cg-RX-API-DMAC10.html)
MA (1) MA27994A1 (cg-RX-API-DMAC10.html)
MX (1) MXPA06001759A (cg-RX-API-DMAC10.html)
MY (1) MY147449A (cg-RX-API-DMAC10.html)
NO (1) NO333306B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ585188A (cg-RX-API-DMAC10.html)
PL (2) PL1660458T3 (cg-RX-API-DMAC10.html)
PT (2) PT1660458E (cg-RX-API-DMAC10.html)
RU (1) RU2395500C2 (cg-RX-API-DMAC10.html)
SG (1) SG145749A1 (cg-RX-API-DMAC10.html)
SI (2) SI2287156T1 (cg-RX-API-DMAC10.html)
TN (1) TNSN06052A1 (cg-RX-API-DMAC10.html)
TW (1) TWI378923B (cg-RX-API-DMAC10.html)
WO (1) WO2005016894A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200600464B (cg-RX-API-DMAC10.html)

Families Citing this family (216)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
RS51752B (sr) 2002-07-29 2011-12-31 Rigel Pharmaceuticals Metode tretiranja i prevencije autoimunih oboljenja jedinjenjima 2,4-pirimidindiamina
NZ540612A (en) 2003-01-14 2008-02-29 Arena Pharm Inc 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP2004313181A (ja) * 2003-04-02 2004-11-11 Canon Inc 感染症起炎菌検出用プローブ及びプローブセット、ならびに担体及び遺伝子検査方法
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
RS53109B (sr) 2003-07-30 2014-06-30 Rigel Pharmaceuticals Inc. Jedinjenja 2,4 pirimidindiamina za upotrebu u tretmanu ili prevenciji autoimunih bolesti
BRPI0413616B8 (pt) * 2003-08-15 2021-05-25 Irm Llc 2,4-pirimidinadiaminas, seus usos, e composição farmacêutica
US8131475B2 (en) * 2003-09-03 2012-03-06 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
NZ551027A (en) 2004-04-08 2011-01-28 Targegen Inc Benzotriazine inhibitors of kinases
EP1598343A1 (de) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
US7521457B2 (en) * 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
JP5275628B2 (ja) 2004-08-25 2013-08-28 ターゲジェン インコーポレーティッド 複素環式化合物および使用方法
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
KR101278397B1 (ko) 2005-01-19 2013-06-25 리겔 파마슈티칼스, 인크. 2,4-피리미딘디아민 화합물의 전구약물 및 이의 용도
CN105348203B (zh) * 2005-06-08 2018-09-18 里格尔药品股份有限公司 抑制jak途径的组合物和方法
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
PE20070362A1 (es) * 2005-07-15 2007-04-23 Glaxo Group Ltd COMPUESTOS DERIVADOS DE INDAZOL-4-IL-2,4-PIRIMIDINDIAMINA COMO INHIBIDORES DE TIROSINA QUINASA (QUINASA Syk)
WO2007028445A1 (en) * 2005-07-15 2007-03-15 Glaxo Group Limited 6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives
GB0517329D0 (en) * 2005-08-25 2005-10-05 Merck Sharp & Dohme Stimulation of neurogenesis
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
BR122021011787B1 (pt) 2005-11-01 2022-01-25 Impact Biomedicines, Inc Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
TW200736232A (en) * 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
WO2007085540A1 (en) * 2006-01-27 2007-08-02 Glaxo Group Limited 1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives
ES2439948T3 (es) 2006-02-17 2014-01-27 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para el tratamiento o la prevención de enfermedades autoinmunitarias
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
ES2561406T3 (es) 2006-04-14 2016-02-26 Cell Signaling Technology, Inc. Defectos de genes y quinasa ALK mutante en tumores sólidos humanos
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
EP1914240B1 (en) 2006-10-11 2009-12-02 Astellas Pharma Inc. EML4-ALK fusion gene
CA2598893C (en) 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
MX2009004426A (es) 2006-10-23 2009-08-12 Cephalon Inc Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met.
GEP20125691B (en) 2006-12-08 2012-11-26 Irm Llc Compounds and compositions as protein kinase inhibitors
KR101149295B1 (ko) * 2006-12-08 2012-07-05 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물
CN101563327A (zh) * 2006-12-19 2009-10-21 健泰科生物技术公司 嘧啶类激酶抑制剂
TW200902010A (en) 2007-01-26 2009-01-16 Smithkline Beecham Corp Anthranilamide inhibitors of aurora kinase
NZ580372A (en) 2007-04-18 2012-01-12 Pfizer Prod Inc Pyrimidine and triazine derivatives including a sulfonamide group for the treatment of abnormal cell growth such as cancer
TWI389893B (zh) * 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
BRPI0814821A2 (pt) * 2007-07-16 2015-02-03 Astrazeneca Ab Composto, composição farmacêutica, e, processo para preparar um composto
US7981903B2 (en) 2007-08-08 2011-07-19 Glaxosmithkline Llc 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer
WO2009032703A1 (en) * 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
JP2010538004A (ja) * 2007-08-28 2010-12-09 アイアールエム・リミテッド・ライアビリティ・カンパニー キナーゼ阻害剤としての２−ビフェニルアミノ−４−アミノピリミジン誘導体
CA2710118A1 (en) 2007-12-20 2009-07-02 Cellzome Limited Sulfamides as zap-70 inhibitors
JP2011512413A (ja) * 2008-02-19 2011-04-21 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｆａｋの阻害剤としてのアニリノピリジン
AU2009233964B2 (en) * 2008-04-07 2012-06-07 Irm Llc Compounds and compositions as protein kinase inhibitors
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
JP5802127B2 (ja) 2008-04-16 2015-10-28 ポートラ ファーマシューティカルズ， インコーポレイテッド Ｓｙｋ又はｊａｋキナーゼ阻害剤としての２，６−ジアミノ−ピリミジン−５−イル−カルボキサミド類
AU2009244897B2 (en) 2008-04-16 2014-11-13 Alexion Pharmaceuticals, Inc. 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
WO2009131687A2 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
PT2300013T (pt) * 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
EA020807B1 (ru) * 2008-06-17 2015-01-30 Астразенека Аб Соединения пиридина
PE20100087A1 (es) 2008-06-25 2010-02-08 Irm Llc Compuestos y composiciones como inhibidores de cinasa
US8445505B2 (en) 2008-06-25 2013-05-21 Irm Llc Pyrimidine derivatives as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
BRPI0914682B8 (pt) * 2008-06-27 2021-05-25 Avila Therapeutics Inc compostos de heteroarila e composições compreendendo os referidos compostos
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
JO3067B1 (ar) * 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
AR074210A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina como inhibidores de ptk2-quinasa
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
AR074830A1 (es) 2008-12-19 2011-02-16 Cephalon Inc Pirrolotriazinas como inhibidores de alk y jak2
SI2565193T1 (sl) 2009-01-23 2014-07-31 Rigel Pharmaceuticals, Inc. Sestavki in metode inhibicije JAK poti
ES2423804T3 (es) 2009-04-03 2013-09-24 Cellzome Gmbh Métodos para la identificación de moléculas que interaccionan con cinasas y para la purificación de proteínas de cinasa
WO2010118986A1 (en) 2009-04-14 2010-10-21 Cellzome Limited Fluoro substituted pyrimidine compounds as jak3 inhibitors
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
TW201100441A (en) * 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
EP2440548A1 (en) * 2009-06-10 2012-04-18 Abbott Laboratories 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors
US20120142667A1 (en) * 2009-06-10 2012-06-07 Nigel Ramsden Pyrimidine derivatives as zap-70 inhibitors
EP2440058A4 (en) 2009-06-12 2012-11-21 Dana Farber Cancer Inst Inc MELTED HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
EP2443106A1 (en) * 2009-06-18 2012-04-25 Cellzome Limited Heterocyclylaminopyrimidines as kinase inhibitors
US20120165332A1 (en) * 2009-06-18 2012-06-28 Cellzome Limited Sulfonamides and sulfamides as zap-70 inhibitors
CA2771675A1 (en) * 2009-09-11 2011-03-17 Cellzome Limited Ortho substituted pyrimidine compounds as jak inhibitors
US20130137709A1 (en) * 2010-05-05 2013-05-30 Nathanael S. Gray Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
WO2012019132A2 (en) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Anaplastic lymphoma kinase in kidney cancer
NZ607845A (en) 2010-08-10 2015-03-27 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
EP2635556B1 (en) 2010-11-01 2017-06-21 Portola Pharmaceuticals, Inc. Benzamides and nicotinamides as syk modulators
WO2012061415A1 (en) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Oxypyrimidines as syk modulators
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CN103269704B (zh) 2010-11-01 2018-07-06 西建卡尔有限责任公司 杂环化合物和其用途
EP2635557A2 (en) 2010-11-01 2013-09-11 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
EP2637502B1 (en) 2010-11-10 2018-01-10 Celgene CAR LLC Mutant-selective egfr inhibitors and uses thereof
PT2646448T (pt) 2010-11-29 2017-10-04 Osi Pharmaceuticals Llc Inibidores macrocíclicos de cinases
KR102325775B1 (ko) * 2010-12-17 2021-11-12 노파르티스 아게 5-클로로-ｎ2-(2-이소프로폭시-5-메틸-4-피페리딘-4-일-페닐)-ｎ4[2-(프로판-2-술포닐)-페닐]-피리미딘-2,4-디아민의 결정질 형태
US8546443B2 (en) 2010-12-21 2013-10-01 Boehringer Ingelheim International Gmbh Benzylic oxindole pyrimidines
JP2012153674A (ja) 2011-01-28 2012-08-16 Astellas Pharma Inc ジ（アリールアミノ）アリール化合物の製造方法及びその合成中間体
PL2670401T3 (pl) * 2011-02-02 2015-11-30 Novartis Ag Sposoby stosowania inhibitorów ALK
WO2012110773A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Fak inhibitors
AU2012216894B2 (en) 2011-02-17 2016-07-14 Cancer Therapeutics Crc Pty Limited Selective FAK inhibitors
US9006241B2 (en) 2011-03-24 2015-04-14 Noviga Research Ab Pyrimidine derivatives
WO2012135641A2 (en) 2011-03-30 2012-10-04 H. Lee Moffitt Cancer Center And Research Institute Aurora kinase inhibitors and methods of making and using thereof
RU2625309C2 (ru) 2011-04-22 2017-07-13 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Замещенные диаминокарбоксамидные и диаминокарбонитрильные производные пиримидинов, их композиции и способы лечения с их помощью
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
TW201325593A (zh) 2011-10-28 2013-07-01 Celgene Avilomics Res Inc 治療布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶疾病或病症之方法
EP3569598A1 (en) 2011-11-17 2019-11-20 Dana Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
US8877760B2 (en) 2011-11-23 2014-11-04 Portola Pharmaceuticals, Inc. Substituted pyrazine-2-carboxamide kinase inhibitors
AU2013229995B2 (en) 2012-03-06 2017-04-13 Cephalon, Inc. Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor
CN108658873B (zh) 2012-03-15 2021-09-14 西建卡尔有限责任公司 表皮生长因子受体激酶抑制剂的固体形式
JP6317320B2 (ja) 2012-03-15 2018-04-25 セルジーン シーエーアール エルエルシー 上皮成長因子受容体キナーゼ阻害剤の塩
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
KR101582852B1 (ko) 2012-05-24 2016-01-07 서울대학교 산학협력단 타우 단백질 매개 신경 퇴행성 질환 치료제
KR101446742B1 (ko) 2012-08-10 2014-10-01 한국화학연구원 Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
EP2903970A4 (en) 2012-10-08 2016-11-30 Portola Pharm Inc SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
CA2890346A1 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
KR102156398B1 (ko) * 2012-11-06 2020-09-15 상하이 포천 파마슈티컬 씨오 엘티디 Ａｌｋ 키나아제 억제제
CN103804299A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
EP2935226A4 (en) 2012-12-21 2016-11-02 Celgene Avilomics Res Inc HETEROARYL COMPOUNDS AND USES THEREOF
EP3939614A1 (en) 2013-01-18 2022-01-19 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
CA2900012A1 (en) 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Erk inhibitors and uses thereof
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
MX2015016332A (es) 2013-05-29 2016-07-20 Cephalon Inc Inhibidores de alk biciclicos fusionados.
CN105338980A (zh) 2013-06-18 2016-02-17 诺华股份有限公司 药物组合
WO2015003658A1 (en) * 2013-07-11 2015-01-15 Betta Pharmaceuticals Co., Ltd Protein tyrosine kinase modulators and methods of use
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
WO2015038868A1 (en) * 2013-09-13 2015-03-19 Cephalon, Inc. Fused bicyclic 2,4-diaminopyrimidine derivatives
RU2550346C2 (ru) 2013-09-26 2015-05-10 Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
WO2015058140A1 (en) 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
ES2676734T3 (es) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
KR102357699B1 (ko) 2013-11-06 2022-02-04 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 발현 프로파일링에 의한 림프종 유형의 하위유형 분류 방법
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
WO2015164604A1 (en) * 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) * 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
DK3179858T3 (da) 2014-08-13 2019-07-22 Celgene Car Llc Forme og sammensætninger af en ERK-inhibitor
WO2016029002A2 (en) * 2014-08-22 2016-02-25 Clovis Oncology, Inc. Growth factor receptor inhibitors
PT3209647T (pt) 2014-10-21 2020-09-10 Ariad Pharma Inc Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidino-2,4-diamina
US9513297B2 (en) 2014-12-16 2016-12-06 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
ES2877642T3 (es) 2014-12-16 2021-11-17 Signal Pharm Llc Formulaciones de 2-(terc-butilamino)-4-((1R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-pirimidin-5-carboxamida
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
EP4445956A3 (en) 2015-01-06 2024-12-04 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
CA2975260C (en) 2015-01-29 2024-05-21 Signal Pharmaceuticals Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
WO2016167511A2 (ko) * 2015-04-14 2016-10-20 한국화학연구원 N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
EP3325432B1 (en) 2015-07-24 2020-09-02 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CN106699743B (zh) * 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
CN106883213B (zh) * 2015-12-15 2021-04-20 合肥中科普瑞昇生物医药科技有限公司 一种egfr和alk激酶的双重抑制剂
WO2018001251A1 (zh) * 2016-06-27 2018-01-04 杭州雷索药业有限公司 苯并呋喃吡唑胺类蛋白激酶抑制剂
SG11201901251SA (en) 2016-08-29 2019-03-28 Univ Michigan Regents Aminopyrimidines as alk inhibitors
KR101876514B1 (ko) * 2016-11-08 2018-07-10 한국화학연구원 신규한 피리미딘화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암 및 염증질환의 예방 또는 치료용 약학적 조성물
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
CN110678182B (zh) 2017-02-24 2022-08-23 大邱庆北尖端医疗产业振兴财团 含有能够穿透血脑屏障的化合物作为预防或治疗脑癌的有效成分的药物组合物
JOP20190281A1 (ar) * 2017-06-13 2019-12-02 Korea Res Inst Chemical Tech مشتق n2، n4 ثنائي فينيل بيريميدين -2، 4- ثنائي أمين، وطريقة لتحضيره، وتركيبة صيدلانية تحتوي على المشتق بوصفه مكون فعال للوقاية من السرطان أو علاجه
MX2020002608A (es) 2017-09-07 2020-09-18 Revolution Medicines Inc Composiciones que comprenden inhibidores de shp2 y metodos para tratar el cáncer.
KR101992621B1 (ko) 2017-12-07 2019-09-27 주식회사 온코빅스 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물
WO2019117813A1 (en) * 2017-12-15 2019-06-20 National University Of Singapore Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
EP3715350B1 (en) * 2017-12-21 2024-05-08 Shenzhen TargetRx, Inc. Arylphosphine oxides for inhibiting kinase activity
JP2021524835A (ja) 2018-04-05 2021-09-16 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド Ａｘｌキナーゼ阻害剤およびその使用
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
JP2022508651A (ja) 2018-10-08 2022-01-19 レヴォリューション・メディスンズ，インコーポレイテッド 癌を処置するためのｓｈｐ２阻害剤組成物および方法
WO2020088390A1 (zh) * 2018-10-29 2020-05-07 江苏先声药业有限公司 作为第四代egfr抑制剂的嘧啶吡唑类化合物
US12522583B2 (en) 2018-11-07 2026-01-13 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
WO2020097400A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
US12415816B2 (en) 2018-11-07 2025-09-16 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
AU2019413694B2 (en) 2018-12-28 2025-03-20 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
US20220064196A1 (en) * 2019-01-17 2022-03-03 Betta Pharmaceuticals Co., Ltd. EGFR Inhibitors, Compositions and Methods Thereof
AU2020232616A1 (en) 2019-03-01 2021-09-09 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
AU2020241258B2 (en) * 2019-03-15 2025-09-11 The General Hospital Corporation Novel small molecule inhibitors of TEAD transcription factors
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
JP2022539208A (ja) 2019-07-03 2022-09-07 スミトモ ファーマ オンコロジー， インコーポレイテッド チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
KR102168179B1 (ko) * 2019-10-31 2020-10-20 주식회사 온코빅스 암세포 성장 억제 효과를 나타내는 신규한 헤테로 고리 치환 피리미딘 유도체 및 그를 포함하는 약제학적 조성물
US11608346B2 (en) 2019-11-04 2023-03-21 Revolution Medicines, Inc. Ras inhibitors
IL320513A (en) 2019-11-04 2025-06-01 Revolution Medicines Inc RAS inhibitors
CR20220240A (es) 2019-11-04 2022-08-03 Revolution Medicines Inc Inhibidores de ras
CN114901662A (zh) 2019-11-08 2022-08-12 锐新医药公司 双环杂芳基化合物及其用途
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
EP4074697B1 (en) * 2019-12-03 2025-05-21 Samjin Pharmaceutical Co., Ltd. Novel adamantane derivatives as inhibitors of focal adhesion kinase
WO2021142026A1 (en) 2020-01-07 2021-07-15 Revolution Medicines, Inc. Shp2 inhibitor dosing and methods of treating cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2021227907A1 (en) * 2020-02-25 2022-09-29 Dana-Farber Cancer Institute, Inc. Potent and selective degraders of ALK
EP4168002A1 (en) 2020-06-18 2023-04-26 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
CA3187757A1 (en) 2020-09-03 2022-03-24 Ethan AHLER Use of sos1 inhibitors to treat malignancies with shp2 mutations
US11690915B2 (en) 2020-09-15 2023-07-04 Revolution Medicines, Inc. Ras inhibitors
US20240051956A1 (en) 2020-12-22 2024-02-15 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
CA3204401A1 (en) * 2021-01-07 2022-07-14 Rima AL-AWAR Isoindolinone aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof
CA3207015A1 (en) * 2021-04-01 2022-10-06 Tae Bo Sim Pyrimidine derivative with inhibitory activity against protein kinases and therapeutic pharmaceutical composition including the same
US12297194B2 (en) 2021-04-02 2025-05-13 Bridge Biotherapeutics, Inc. N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof
EP4320153A1 (en) 2021-04-09 2024-02-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of anaplastic large cell lymphoma
CR20230558A (es) 2021-05-05 2024-01-24 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cáncer
CN118561952A (zh) 2021-05-05 2024-08-30 锐新医药公司 Ras抑制剂
CN117500811A (zh) 2021-05-05 2024-02-02 锐新医药公司 共价ras抑制剂及其用途
EP4359570A4 (en) 2021-06-25 2025-04-30 Foundation Medicine, Inc. METHODS OF USING SOMATIC HLA-I LOH TO PREDICT RESPONSE IN IMMUNE CHECKPOINT INHIBITOR-TREATED PATIENTS WITH LUNG CANCER
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
US20250282782A1 (en) 2021-12-17 2025-09-11 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
EP4536364A1 (en) 2022-06-10 2025-04-16 Revolution Medicines, Inc. Macrocyclic ras inhibitors
KR20240143136A (ko) 2023-03-23 2024-10-02 청주대학교 산학협력단 콘크리트 양생용 광발열 단열시트 및 콘크리트 구조물의 조기 시공 방법
CR20250458A (es) 2023-03-30 2025-11-21 Revolution Medicines Inc Composiciones para inducir la hidrólisis de ras gtp y sus usos
KR20260005904A (ko) 2023-04-07 2026-01-12 레볼루션 메디슨즈, 인크. 매크로사이클릭 ras 억제제
AU2024251341A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
AU2024252105A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
CN121335887A (zh) * 2023-06-08 2026-01-13 希格生科（深圳）有限公司 含氮芳环化合物及其医药用途
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL129020C (cg-RX-API-DMAC10.html) 1964-12-15
US3432493A (en) * 1966-06-27 1969-03-11 Abbott Lab Substituted sulfanilamides
SU194829A1 (ru) * 1966-07-08 1967-04-12 Замещенных 5,6-дигидропирроло-
US3367149A (en) * 1966-12-15 1968-02-06 Minnesota Mining & Mfg Radiant white light source
EP0002341B1 (en) * 1977-11-28 1982-01-20 Barry Boettcher Complexes of bivalent copper, methods of preparation thereof and compositions containing said complexes
JPS5964558A (ja) * 1982-09-30 1984-04-12 三菱電機株式会社 耐熱軟質複合体の製造法
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
JP4135318B2 (ja) 1997-12-15 2008-08-20 アステラス製薬株式会社 新規なピリミジン−５−カルボキサミド誘導体
CZ299380B6 (cs) * 1998-03-27 2008-07-09 Janssen Pharmaceutica N. V. Pyrimidinová sloucenina, použití této slouceniny pro prípravu léciva, farmaceutický prostredek tutoslouceninu obsahující, zpusob prípravy tohoto prostredku a uvedené slouceniny a kombinace a produktuvedenou slouceninu obsahující
JP2002523497A (ja) * 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
JP4622047B2 (ja) * 1999-06-09 2011-02-02 アステラス製薬株式会社 新規なヘテロ環カルボキサミド誘導体
ATE288420T1 (de) * 1999-06-09 2005-02-15 Yamanouchi Pharma Co Ltd Neuartige heterocyclische carboxamid-derivate
WO2001025220A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
US6376770B1 (en) * 2000-02-28 2002-04-23 Douglas Hyde Quick connecting universal electrical box and wiring system
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US20020132823A1 (en) 2001-01-17 2002-09-19 Jiahuai Han Assay method
CA2451128A1 (en) * 2001-06-26 2003-01-09 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US6939874B2 (en) * 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
MXPA04004176A (es) * 2001-11-01 2004-09-06 Janssen Pharmaceutica Nv Derivados de aminobenzamida como inhibidores de cinasa 3beta de glicogeno sintasa.
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CA2476281A1 (en) 2002-02-08 2003-08-14 Smithkline Beecham Corporation Pyrimidine compounds
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003231231A1 (en) 2002-05-06 2003-11-11 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
US7449456B2 (en) * 2002-06-28 2008-11-11 Astellas Pharma, Inc. Diaminopyrimidinecarboxamide derivative
RS51752B (sr) * 2002-07-29 2011-12-31 Rigel Pharmaceuticals Metode tretiranja i prevencije autoimunih oboljenja jedinjenjima 2,4-pirimidindiamina
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
CL2004000192A1 (es) * 2003-02-07 2005-03-18 Janssen Pharmaceutica Nv Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja.
DE602004021472D1 (en) * 2003-02-20 2009-07-23 Smithkline Beecham Corp Pyrimiidinverbindungen
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
BRPI0412596A (pt) * 2003-07-16 2006-09-19 Janssen Pharmaceutica Nv derivados de triazolopirimidina como inibores de glicogênio sintase cinase 3
ATE413404T1 (de) * 2003-07-16 2008-11-15 Janssen Pharmaceutica Nv Triazolopyrimidin derivate als inhibitoren von glycogen synthase kinase-3
JP4741491B2 (ja) * 2003-08-07 2011-08-03 ライジェル ファーマシューティカルズ， インコーポレイテッド 抗増殖剤としての２，４−ピリミジンジアミン化合物および使用
BRPI0413616B8 (pt) * 2003-08-15 2021-05-25 Irm Llc 2,4-pirimidinadiaminas, seus usos, e composição farmacêutica
GB0321710D0 (en) * 2003-09-16 2003-10-15 Novartis Ag Organic compounds
CN100584832C (zh) * 2003-09-18 2010-01-27 诺瓦提斯公司 可用于治疗增殖性病症的2,4-二(苯基氨基)嘧啶类
CA2584295C (en) 2004-11-24 2014-08-26 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses

Similar Documents

Publication Publication Date Title
JP2010241830A5 (cg-RX-API-DMAC10.html)
JP2013510120A5 (cg-RX-API-DMAC10.html)
AU2014219283C1 (en) Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
JP5323289B1 (ja) 新規ピペリジン化合物又はその塩
JP2011515397A5 (cg-RX-API-DMAC10.html)
JP2012513416A5 (cg-RX-API-DMAC10.html)
JP2014513704A5 (cg-RX-API-DMAC10.html)
JP2014503574A5 (cg-RX-API-DMAC10.html)
JP2020531447A5 (cg-RX-API-DMAC10.html)
JP2014500870A5 (cg-RX-API-DMAC10.html)
JP2014526549A5 (cg-RX-API-DMAC10.html)
JP2008535903A5 (cg-RX-API-DMAC10.html)
JP2009504763A5 (cg-RX-API-DMAC10.html)
JP2006524669A5 (cg-RX-API-DMAC10.html)
MY170656A (en) Kinase inhibitors
JP2017528467A5 (cg-RX-API-DMAC10.html)
JP2013544846A5 (cg-RX-API-DMAC10.html)
JP2014528433A5 (cg-RX-API-DMAC10.html)
JP2011509949A5 (cg-RX-API-DMAC10.html)
JP2020504716A5 (cg-RX-API-DMAC10.html)
JP2014518544A5 (cg-RX-API-DMAC10.html)
JP2016040288A5 (cg-RX-API-DMAC10.html)
JP2017511321A5 (cg-RX-API-DMAC10.html)
JP2013542261A5 (cg-RX-API-DMAC10.html)
JP2017526677A5 (cg-RX-API-DMAC10.html)